Nikiforov Yuri E
Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45267-0529, USA.
Endocr Pathol. 2004 Winter;15(4):319-27. doi: 10.1385/ep:15:4:319.
Recent molecular studies have provided new insights into thyroid carcinogenesis. In thyroid papillary carcinomas at least three initiating events may occur, which are point mutations in the BRAF and RAS genes and RET/PTC rearrangements. Tumors harboring mutant BRAF and RAS are prone to progression to poorly differentiated and anaplastic carcinoma, but most likely require additional mutations to trigger this process. In thyroid follicular carcinomas, two known initiating events are RAS mutations and PAX8-PPARgamma rearrangements, and RAS predisposes to dedifferentiation of follicular carcinomas. p53 and beta-catenin mutations, found with increasing incidence in poorly differentiated and anaplastic carcinomas but not in well-differentiated tumors, may serve as a direct molecular trigger of tumor dedifferentiation. Additional evidence for progression from a preexisting well-differentiated carcinoma to poorly differentiated and anaplastic carcinoma comes from the studies of loss of heterozygosity and comparative genomic hybridization. Molecular studies, although limited by the lack of uniform histologic criteria for poorly differentiated carcinomas, revealed no genetic mutations or chromosomal abnormalities that are unique for poorly differentiated carcinoma and not present in well-differentiated or anaplastic carcinomas. This suggests that poorly differentiated carcinoma, as a group, represents a distinct step in the evolution from well-differentiated to anaplastic thyroid carcinoma, rather than an entirely separate type of thyroid malignancy.
最近的分子研究为甲状腺癌发生提供了新的见解。在甲状腺乳头状癌中,至少可能发生三种起始事件,即BRAF和RAS基因的点突变以及RET/PTC重排。携带BRAF和RAS突变的肿瘤易于进展为低分化和未分化癌,但很可能需要额外的突变来触发这一过程。在甲状腺滤泡癌中,两种已知的起始事件是RAS突变和PAX8-PPARγ重排,并且RAS易导致滤泡癌去分化。p53和β-连环蛋白突变在低分化和未分化癌中的发生率越来越高,但在高分化肿瘤中未发现,可能作为肿瘤去分化的直接分子触发因素。从先前存在的高分化癌进展为低分化和未分化癌的更多证据来自杂合性缺失和比较基因组杂交研究。分子研究虽然受到低分化癌缺乏统一组织学标准的限制,但未发现低分化癌特有的、高分化或未分化癌中不存在的基因突变或染色体异常。这表明,作为一个群体,低分化癌代表了从高分化甲状腺癌向未分化甲状腺癌演变过程中的一个独特阶段,而不是一种完全独立的甲状腺恶性肿瘤类型。